Gardasil

Pre-clinicalUNKNOWN

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Genital Human Papilloma Virus Infection

Conditions

Genital Human Papilloma Virus Infection

Trial Timeline

Sep 1, 2009 → Oct 1, 2012

NCT ID

NCT01133509

About Gardasil

Gardasil is a pre-clinical stage product being developed by Merck for Genital Human Papilloma Virus Infection. The current trial status is unknown. This product is registered under clinical trial identifier NCT01133509. Target conditions include Genital Human Papilloma Virus Infection.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04022148	Pre-clinical	UNKNOWN	Aug 1, 2019	Dec 31, 2020	Cancer of Cervix
NCT01432574	Phase 2	Completed	Feb 19, 2013	Nov 3, 2020	Human Papillomavirus
NCT01741012	Phase 1	Completed	Jan 1, 2013	Nov 1, 2015	Systemic Lupus Erythematosus
NCT01338051	Phase 1	Completed	May 1, 2011	Apr 1, 2012	Cervical Intraepithelial Neoplasia
NCT00925288	Approved	Completed	Oct 1, 2009	Aug 1, 2011	Human Papillomavirus Infection
NCT01133509	Pre-clinical	UNKNOWN	Sep 1, 2009	Oct 1, 2012	Genital Human Papilloma Virus Infection
NCT00786409	Pre-clinical	Completed	Nov 1, 2008	Dec 1, 2011	Systemic Lupus Erythematosus
NCT00666107	Pre-clinical	UNKNOWN	Jun 1, 2008	Jun 1, 2012	Anal Cancer

Competing Products

20 competing products in Genital Human Papilloma Virus Infection

See all competitors

Product	Company	Stage	Hype Score
Tideglusib	AMO Pharma	Pre-clinical	15
Tideglusib + Placebo	AMO Pharma	Phase 2/3	57
Tideglusib	AMO Pharma	Phase 2/3	57
Fulvestrant + Abemaciclib	Eli Lilly	Phase 2	52
EDIT-101	Editas Medicine	Phase 1/2	33
Gemcitabine + liposomal doxorubicin	Eli Lilly	Phase 3	77
Tildacerfont/Placebo	Spruce Biosciences	Phase 2	44
SPR001	Spruce Biosciences	Phase 2	44
SPR001	Spruce Biosciences	Phase 2	44
Tildacerfont/Placebo	Spruce Biosciences	Phase 2	44
Tildacerfont	Spruce Biosciences	Phase 2	44
ASP2151 + Placebo	Astellas Pharma	Phase 1	33
ASP2151 + valacyclovir + Placebo	Astellas Pharma	Phase 2	52
Tildrakizumab 100 mg + Placebo	Sun Pharmaceutical	Phase 3	77
Topical NO + Placebo	Kyowa Kirin	Phase 2	52
KW-3357	Kyowa Kirin	Phase 1	33
Ixekizumab + Placebo	Eli Lilly	Phase 3	77
Gemcitabine + Paclitaxel + Carboplatin	Eli Lilly	Phase 3	77
Daratumumab	Johnson & Johnson	Phase 2	52
Risankizumab + Placebo for Risankizumab	AbbVie	Approved	85

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved